COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
- PMID: 33819751
- PMCID: PMC7973080
- DOI: 10.1016/j.esmoop.2021.100100
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
Abstract
High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients' needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: 'how can we deal with COVID-19 infection in cancer patients?' In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health care professionals and institutions in the decision-making processes the pandemic has engendered within this scenario. The relevant documents as well as the educational and institutional initiatives the AIOM has taken are reported in this article.
Keywords: AIOM; COVID-19; cancer; treatment; vaccination.
Copyright © 2021. Published by Elsevier Ltd.
Conflict of interest statement
Disclosure NS has served as a consultant for Celgene and Isheo; MDM has served as a consultant for AstraZeneca, Takeda, Pfizer, Novartis, Roche, Janssen, Astellas, Elisai; UDG has served as a consultant for Janssen, Astellas Pharma, Sanofi, Bayer, Pfizer, Bristol-Myers Squibb (BMS), Novartis, Ipsen, and Merck Sharp & Dohme (MSD); MT has served as a consultant for Janssen, Astellas Pharma, Sanofi, Bayer, Pfizer, Novartis; DG has served as a consultant for Pfizer, Ipsen, Novartis, Merck; RC has served as a consultant for Novartis, Pfizer, Roche, Takeda, AstraZeneca, BMS, MSD; NLV has served as a consultant for Novartis, Pfizer, Roche, Gentili, Celgene, EISAI, MSD; LDM has served as a consultant for Roche, Novartis, Eli Lilly, Pfizer, MSD, Ipsen, Takeda, Celgene, Eisai, Genomic Health, General Electrics, Amgen, Pierre Fabre, Daiichi Sankyo, AstraZeneca; FP has served as consultant for Roche, Bayer, AstraZeneca, Pierre Fabre, Janssen Cilag, Ipsen; SC has served as consultant for Eli Lilly; GB has served as consultant for Roche, Servier, Celgene, Ipsen, Sanofi, Merck Serono. AR has declared no conflicts of interest.
References
-
- Marron J.M., Joffe S., Jagsi R., Spence R.A., Hlubocky F.J. Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. J Clin Oncol. 2020;38:2201–2205. - PubMed
-
- Van de Haar J., Hoes L.R., Coles C.E. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020;26:665–671. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
